ArticleDrug design, development and therapy2022

A Novel Glycyrrhetinic Acid-Modified Oxaliplatin Liposome for Liver-Targeting and in vitro/vivo Evaluation [Retraction].

PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.